|Bid||0.00 x 1200|
|Ask||0.00 x 1800|
|Day's range||5.38 - 5.61|
|52-week range||4.02 - 43.12|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||02 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.27|
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March
Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...
FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.